Which one of the following choices describes the action of niraparib?
A. A cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor.
B. An indoleamine 2,3-dioxygenase (IDO) inhibitor.
C. A poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2 inhibitor.
D. A programmed death 1 (PD-1) inhibitor.
Read the study associated with this question on NEJM Resident...
View details ⇨
Niraparib Maintenance Therapy in Ovarian Cancer | NEJM Resident 360